Organization · Venture Capital
3B Future Health Fund I & II
3B Future Health Fund I & II is a Luxembourg-based venture capital fund focused on early-stage investments in healthcare startups, particularly in oncology and rare diseases. The fund primarily invests in companies located in Europe, the US, and Israel.
Overview
What 3B Future Health Fund I & II does
What 3B Future Health Fund I & II is
3B Future Health Fund I & II is a Luxembourg-based venture capital fund focused on early-stage investments in healthcare startups, particularly in oncology and rare diseases. The fund primarily invests in companies located in Europe, the US, and Israel.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2016
- Approximate age
- About 10 years
- Structured capabilities
- Funder
- Last reviewed
- March 18, 2026
Official channels
Find 3B Future Health Fund I & II elsewhere
Open the official website or a supported primary organization account.
Capability profile
3B Future Health Fund I & II as a funder
Investment thesis
3B Future Health Fund I & II focuses on early-stage healthcare companies that address high unmet medical needs, particularly in oncology and rare diseases. The fund aims to support innovative solutions that can significantly impact patient care.
Focus narrative
The fund primarily invests in early-stage companies located in the US, Europe, and Israel, targeting sectors with substantial unmet patient needs. While it typically engages with companies raising Series A rounds, it is open to investing at earlier stages. The fund aims to build a diversified portfolio of 10-15 companies, with investments up to $12 million in each, while also reserving capital for follow-on rounds.
Value beyond capital
3B Future Health Fund provides strategic support and guidance to its portfolio companies, leveraging the expertise of its experienced team in drug development and healthcare. The fund aims to facilitate growth through capital investment and access to a network of industry connections.
Terms and economics
- Typical check
- $1,000,000–$12,000,000
- Sweet spot
- $6,000,000
Focus and fit
- Stages
- Seed · Series A · Series A+
- Regions
- Europe · Global · North America
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 20
- Recorded notable exits
- AMAL Therapeutics
Portfolio context
Notable portfolio companies include: NeoPhore: Collaborating with The Institute of Cancer Research on cancer research. Geneos Therapeutics: Raised $5 million in Series A3 financing. iOnctura: Awarded EUR 17.5 million for developing a novel pancreatic cancer therapy. AnaCardio: Received regulatory approval for a Phase 1b/2a clinical study in heart failure. Domain Therapeutics: Advancing into clinical trials with its EP4R antagonist in solid tumors. Sibylla Biotech: Raised €23 million to enhance its protein degradation pipeline.
Common questions
What to know about 3B Future Health Fund I & II
Upseed classifies 3B Future Health Fund I & II under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 18, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.